Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival.
Chemotherapy
Immunotherapy
Nutrition
Overall survival
Radiation
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
16
02
2024
accepted:
07
07
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Lung cancer remains a serious medical problem. The trace element selenium seems to be a promising prognostic marker or therapeutic option for cancer patients. We enrolled 99 patients with histologically confirmed NSCLC undergoing radiotherapy. The serum selenium level of these patients was determined prior to irradiation (t0), after reaching 20 Gy (t1), and at the end of radiotherapy (t2). Selenium concentrations were measured with total-reflection X‑ray fluorescence (TXRF) spectroscopy. We formed three subgroups according to the change in serum selenium levels across timepoints, and Kaplan-Meier analysis was used to estimate overall survival (OS). Further subgroups were patients with/without metastatic disease. We used adjusted Cox regression models. The change in selenium concentration was especially significant between t0 and t1 for the whole study group (hazard ratio [HR] = 0.5, p = 0.03) as well as in patients with metastasized NSCLC (HR = 0.3, p = 0.04) after adjustment. The baseline selenium value in patients with non-metastasized NSCLC was associated with overall survival (HR = 0.3, p = 0.04). The change in selenium levels between t0 and t2 was significant in patients with metastatic lung cancer (HR = 0.1, p = 0.03). Patients with increased serum selenium levels during radiotherapy between the start of treatment (t0) and t1 had better OS (HR = 0.46, p = 0.05). Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer remains a serious medical problem. The trace element selenium seems to be a promising prognostic marker or therapeutic option for cancer patients.
METHODS
METHODS
We enrolled 99 patients with histologically confirmed NSCLC undergoing radiotherapy. The serum selenium level of these patients was determined prior to irradiation (t0), after reaching 20 Gy (t1), and at the end of radiotherapy (t2). Selenium concentrations were measured with total-reflection X‑ray fluorescence (TXRF) spectroscopy. We formed three subgroups according to the change in serum selenium levels across timepoints, and Kaplan-Meier analysis was used to estimate overall survival (OS). Further subgroups were patients with/without metastatic disease. We used adjusted Cox regression models.
RESULTS
RESULTS
The change in selenium concentration was especially significant between t0 and t1 for the whole study group (hazard ratio [HR] = 0.5, p = 0.03) as well as in patients with metastasized NSCLC (HR = 0.3, p = 0.04) after adjustment. The baseline selenium value in patients with non-metastasized NSCLC was associated with overall survival (HR = 0.3, p = 0.04). The change in selenium levels between t0 and t2 was significant in patients with metastatic lung cancer (HR = 0.1, p = 0.03). Patients with increased serum selenium levels during radiotherapy between the start of treatment (t0) and t1 had better OS (HR = 0.46, p = 0.05).
CONCLUSION
CONCLUSIONS
Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.
Identifiants
pubmed: 39240366
doi: 10.1007/s00066-024-02276-w
pii: 10.1007/s00066-024-02276-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Delaney GP, Barton MB (2015) Evidence-based estimates of the demand for radiotherapy. Clin Oncol 27(2):70–76. https://doi.org/10.1016/j.clon.2014.10.005
doi: 10.1016/j.clon.2014.10.005
de Mello RA, Neves NM, Tadokoro H, Amaral GA, Castelo-Branco P, Zia VAA (2020) New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med 9(11):3543. https://doi.org/10.3390/jcm9113543
doi: 10.3390/jcm9113543
pubmed: 33153004
pmcid: 7693900
Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X (2022) Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol 18(14):1757–1775. https://doi.org/10.2217/fon-2021-0862
doi: 10.2217/fon-2021-0862
pubmed: 35232247
Krug D, Dunst J (2023) Stereotaktische Radiotherapie plus Nivolumab bei NSCLC. Strahlenther Onkol 199(10):957–959. https://doi.org/10.1007/s00066-023-02143-0 (Stereotactic radiotherapy plus nivolumab in the treatment of non-small-cell lung cancer)
doi: 10.1007/s00066-023-02143-0
pubmed: 37640868
pmcid: 10542284
Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2023) First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02175-6
doi: 10.1007/s00066-023-02175-6
pubmed: 37975883
pmcid: 11186867
Memmott RM, Wolfe AR, Carbone DP, Williams TM (2021) Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol 16(7):1086–1098. https://doi.org/10.1016/j.jtho.2021.03.017
doi: 10.1016/j.jtho.2021.03.017
pubmed: 33845212
Puspitasari IM, Abdulah R, Yamazaki C et al (2014) Updates on clinical studies of selenium supplementation in radiotherapy. Radiat Oncol 9:125. https://doi.org/10.1186/1748-717X-9-125
doi: 10.1186/1748-717X-9-125
pubmed: 24885670
pmcid: 4073179
Jaworska K, Gupta S, Durda K, Muszyńska M, Sukiennicki G, Jaworowska E, Grodzki T, Sulikowski M, Waloszczyk P, Wójcik J, Lubiński J, Cybulski C, Dębniak T, Lener M, Morawski AW, Krzystolik K, Narod SA, Sun P, Lubiński J, Jakubowska A (2013) A low selenium level is associated with lung and laryngeal cancers. PLoS ONE 8(3):e59051. https://doi.org/10.1371/journal.pone.0059051 (Erratum in: PLoS One. 2013;8(8). https://doi.org/10.1371/annotation/f777aaec-b6b8-4480-9cce-18e0f1b8e5d5 )
doi: 10.1371/journal.pone.0059051
pubmed: 23516596
pmcid: 3596323
Kieliszek M, Bano I, Zare H (2022) A comprehensive review on selenium and its effects on human health and distribution in middle eastern countries. Biol Trace Elem Res 200(3):971–987. https://doi.org/10.1007/s12011-021-02716-z
doi: 10.1007/s12011-021-02716-z
pubmed: 33884538
Ibrahim SAZ, Kerkadi A, Agouni A (2019) Selenium and health: an update on the situation in the Middle East and North Africa. Nutrients 11(7):1457. https://doi.org/10.3390/nu11071457
doi: 10.3390/nu11071457
pubmed: 31252568
pmcid: 6682981
Schilling D, Herold B, Combs SE, Schmid TE (2019) Selenium does not affect radiosensitivity of breast cancer cell lines. Radiat Environ Biophys 58(3):433–438. https://doi.org/10.1007/s00411-019-00801-5
doi: 10.1007/s00411-019-00801-5
pubmed: 31201502
Lobb RJ, Jacobson GM, Cursons RT, Jameson MB (2018) The interaction of selenium with chemotherapy and radiation on normal and malignant human mononuclear blood cells. Int J Mol Sci 19(10):3167. https://doi.org/10.3390/ijms19103167
doi: 10.3390/ijms19103167
pubmed: 30326581
pmcid: 6214079
Tian J, Wei X, Zhang W, Xu A (2020) Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Front Bioeng Biotechnol 16(8):598997. https://doi.org/10.3389/fbioe.2020.598997
doi: 10.3389/fbioe.2020.598997
Handa E, Puspitasari IM, Abdulah R, Yamazaki C, Kameo S, Nakano T, Koyama H (2020) Recent advances in clinical studies of selenium supplementation in radiotherapy. J Trace Elem Med Biol 62:126653. https://doi.org/10.1016/j.jtemb.2020.126653
doi: 10.1016/j.jtemb.2020.126653
pubmed: 32998101
Hoeflich J, Hollenbach B, Behrends T, Hoeg A, Stosnach H, Schomburg L (2010) The choice of biomarkers determines the selenium status in young German vegans and vegetarians. Br J Nutr 104(11):1601–1604. https://doi.org/10.1017/S0007114510002618
doi: 10.1017/S0007114510002618
pubmed: 20637135
Hughes DJ, Fedirko V, Jenab M, Schomburg L, Méplan C, Freisling H, Bueno-de-Mesquita HB, Hybsier S, Becker NP, Czuban M, Tjønneland A, Outzen M, Boutron-Ruault MC, Racine A, Bastide N, Kühn T, Kaaks R, Trichopoulos D, Trichopoulou A, Lagiou P, Panico S, Peeters PH, Weiderpass E, Skeie G, Dagrun E, Chirlaque MD, Sánchez MJ, Ardanaz E, Ljuslinder I, Wennberg M, Bradbury KE, Vineis P, Naccarati A, Palli D, Boeing H, Overvad K, Dorronsoro M, Jakszyn P, Cross AJ, Quirós JR, Stepien M, Kong SY, Duarte-Salles T, Riboli E, Hesketh JE (2015) Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer 136(5):1149–1161. https://doi.org/10.1002/ijc.29071
doi: 10.1002/ijc.29071
pubmed: 25042282
Cabral M, Kuxhaus O, Eichelmann F, Kopp JF, Alker W, Hackler J, Kipp AP, Schwerdtle T, Haase H, Schomburg L, Schulze MB (2021) Trace element profile and incidence of type 2 diabetes, cardiovascular disease and colorectal cancer: results from the EPIC-Potsdam cohort study. Eur J Nutr 60(6):3267–3278. https://doi.org/10.1007/s00394-021-02494-3
doi: 10.1007/s00394-021-02494-3
pubmed: 33590281
pmcid: 8354864
Baker JR, Umesh S, Jenab M, Schomburg L, Tjønneland A, Olsen A, Boutron-Ruault MC, Rothwell JA, Severi G, Katzke V, Johnson T, Schulze MB, Masala G, Agnoli C, Simeon V, Tumino R, Bueno-de-Mesquita HB, Gram IT, Skeie G, Bonet C, Rodriguez-Barranco M, Houerta JM, Gylling B, Van Guelpen B, Perez-Cornago A, Aglago E, Freisling H, Weiderpass E, Cross AJ, Heath AK, Hughes DJ, Fedirko V (2021) Prediagnostic blood selenium status and mortality among patients with colorectal cancer in Western European populations. Biomedicines 9(11):1521. https://doi.org/10.3390/biomedicines9111521
doi: 10.3390/biomedicines9111521
pubmed: 34829750
pmcid: 8614984
Hughes DJ, Duarte-Salles T, Hybsier S, Trichopoulou A, Stepien M, Aleksandrova K, Overvad K, Tjønneland A, Olsen A, Affret A, Fagherazzi G, Boutron-Ruault MC, Katzke V, Kaaks R, Boeing H, Bamia C, Lagiou P, Peppa E, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, Engeset D, Weiderpass E, Lasheras C, Agudo A, Sánchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Hemmingsson O, Wareham NJ, Khaw KT, Bradbury KE, Cross AJ, Gunter M, Riboli E, Romieu I, Schomburg L, Jenab M (2016) Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 104(2):406–414. https://doi.org/10.3945/ajcn.116.131672
doi: 10.3945/ajcn.116.131672
pubmed: 27357089
Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, Malmberg M, Saal LH, Rydén L, Borg Å, Manjer J, Schomburg L (2021) Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: a multicentre cohort study. Redox Biol 47:102145. https://doi.org/10.1016/j.redox.2021.102145
doi: 10.1016/j.redox.2021.102145
pubmed: 34563873
pmcid: 8476451
Pietrzak S, Wójcik J, Scott RJ, Kashyap A, Grodzki T, Baszuk P, Bielewicz M, Marciniak W, Wójcik N, Dębniak T, Masojć B, Pieróg J, Cybulski C, Gronwald J, Wojtyś M, Kubisa B, Sukiennicki G, Deptuła J, Waloszczyk P, Jakubowska A, Lubiński J, Lener MR (2019) Influence of the selenium level on overall survival in lung cancer. J Trace Elem Med Biol 56:46–51. https://doi.org/10.1016/j.jtemb.2019.07.010
doi: 10.1016/j.jtemb.2019.07.010
pubmed: 31442953
Lubiński J, Marciniak W, Muszynska M, Jaworowska E, Sulikowski M, Jakubowska A, Kaczmarek K, Sukiennicki G, Falco M, Baszuk P, Mojsiewicz M, Kotsopoulos J, Sun P, Narod SA, Lubiński JA (2018) Serum selenium levels and the risk of progression of laryngeal cancer. PLoS ONE 13(1):e184873. https://doi.org/10.1371/journal.pone.0184873 (Erratum in: PLoS One. 2018 Mar 12;13(3):e0194469)
doi: 10.1371/journal.pone.0184873
pubmed: 29304040
pmcid: 5755727
Fraunholz I, Eberlein K, Schopohl B, Böttcher HD, Rödel C (2008) Selenium levels during the course of radiotherapy. No influence of irradiation on blood selenium concentration. Strahlenther Onkol 184(8):411–415. https://doi.org/10.1007/s00066-008-1867-6
doi: 10.1007/s00066-008-1867-6
pubmed: 18956518
Lopez-Saez JB, Senra-Varela A, Pousa-Estevez L (2003) Selenium in breast cancer. Oncology 64(3):227–231. https://doi.org/10.1159/000069312
doi: 10.1159/000069312
pubmed: 12697962
Schomburg L (2022) Selenoprotein P—Selenium transport protein, enzyme and biomarker of selenium status. Free Radic Biol Med 191:150–163. https://doi.org/10.1016/j.freeradbiomed.2022.08.022
doi: 10.1016/j.freeradbiomed.2022.08.022
pubmed: 36067902
Franca CAS, Nogueira CR, Ramalho A, Carvalho ACP, Vieira SL, Penna ABRC (2011) Serum levels of selenium in patients with breast cancer before and after treatment of external beam radiotherapy. Ann Oncol 22(5):1109–1112. https://doi.org/10.1093/annonc/mdq547
doi: 10.1093/annonc/mdq547
pubmed: 20924074
Yadav SP, Gera A, Singh I, Chanda R (2002) Serum selenium levels in patients with head and neck cancer. J Otolaryngol 31(4):216–219. https://doi.org/10.2310/7070.2002.21096
doi: 10.2310/7070.2002.21096
pubmed: 12240756
Zeng YC, Xue M, Chi F, Xu ZG, Fan GL, Fan YC, Zheng MH, Zhong WZ, Wang SL, Zhang ZY, Chen XD, Wu LN, Jin XY, Chen W, Li Q, Zhang XY, Xiao YP, Wu R, Guo QY (2012) Serum levels of selenium in patients with brain metastases from non-small cell lung cancer before and after radiotherapy. Cancer Radiother 16(3):179–182. https://doi.org/10.1016/j.canrad.2011.11.003
doi: 10.1016/j.canrad.2011.11.003
pubmed: 22521871
Elango S, Samuel S, Khashim Z, Subbiah U (2018) Selenium influences trace elements homeostasis, cancer Biomarkers in squamous cell carcinoma patients administered with cancerocidal radiotherapy. Asian Pac J Cancer Prev 19(7):1785–1792. https://doi.org/10.22034/APJCP.2018.19.7.1785
doi: 10.22034/APJCP.2018.19.7.1785
pubmed: 30049188
pmcid: 6165669
Muecke R, Schomburg L, Glatzel M, Berndt-Skorka R, Baaske D, Reichl B, Buentzel J, Kundt G, Prott FJ, Devries A, Stoll G, Kisters K, Bruns F, Schaefer U, Willich N, Micke O, German Working Group Trace Elements and Electrolytes in Oncology-AKTE. (2010) Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 78(3):828–835. https://doi.org/10.1016/j.ijrobp.2009.08.013
doi: 10.1016/j.ijrobp.2009.08.013
pubmed: 20133068
Muecke R, Micke O, Schomburg L, Glatzel M, Reichl B, Kisters K, Schaefer U, Huebner J, Eich HT, Fakhrian K, Adamietz IA, Buentzel J, German Working Group Trace Elements and Electrolytes in Oncology-AKTE (2014) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther 13(6):463–467. https://doi.org/10.1177/1534735414541963
doi: 10.1177/1534735414541963
pubmed: 25015649
Muecke R, Micke O, Schomburg L, Buentzel J, Kisters K, Adamietz IA (2018) Selenium in radiation oncology-15 years of experiences in Germany. Nutrients 10(4):483. https://doi.org/10.3390/nu10040483
doi: 10.3390/nu10040483
pubmed: 29652817
pmcid: 5946268
Chen YC, Prabhu KS, Mastro AM (2013) Is selenium a potential treatment for cancer metastasis? Nutrients 5(4):1149–1168. https://doi.org/10.3390/nu5041149
doi: 10.3390/nu5041149
pubmed: 23567478
pmcid: 3705340
Zachara BA, Marchaluk-Wiśniewska E, Maciag A, Pepliński J, Skokowski J, Lambrecht W (1997) Decreased selenium concentration and glutathione peroxidase activity in blood and increase of these parameters in malignant tissue of lung cancer patients. Lung 175(5):321–332. https://doi.org/10.1007/pl00007578
doi: 10.1007/pl00007578
pubmed: 9270989
Chen QW, Zhu XY, Li YY, Meng ZQ. (2014) Epigenetic regulation and cancer (review). Oncol Rep 31(2):523–532. https://doi.org/10.3892/or.2013.2913
doi: 10.3892/or.2013.2913
pubmed: 24337819